Overview

Nisin is a naturally occurring antimicrobial peptide produced by Lactococcus lactis bacteria and has been used as a food preservative for decades. Research suggests this 34-amino acid lantibiotic demonstrates potent antibacterial activity against gram-positive bacteria by disrupting bacterial cell membranes. Studies indicate nisin may have therapeutic potential beyond its antimicrobial properties, including anticancer effects and antiviral activity against SARS-CoV-2.

The peptide belongs to the lantibiotic family, characterized by unique post-translational modifications that create ring structures essential for its biological activity. Clinical trials are currently investigating nisin's therapeutic applications in oral cancer, peri-implantitis, and other conditions.

Mechanism of Action

Nisin exerts its antimicrobial effects through multiple mechanisms:

Membrane Disruption: Nisin binds to lipid II, a precursor in bacterial cell wall synthesis, creating pores in the bacterial membrane. This leads to rapid depolarization and cell death in gram-positive bacteria.

Cell Wall Synthesis Inhibition: The peptide interferes with peptidoglycan synthesis by sequestering lipid II, preventing proper cell wall formation during bacterial division.

Spore Inhibition: Research indicates nisin can prevent spore outgrowth in Bacillus and Clostridium species by targeting germination mechanisms.

Anticancer Activity: Studies suggest nisin ZP induces apoptosis in cancer cells through mitochondrial membrane disruption and activation of caspase pathways, particularly in non-small cell lung cancer.

Antiviral Properties: Recent research indicates nisin may interact with the SARS-CoV-2 spike protein and human ACE2 receptor, potentially interfering with viral entry.

Research Summary

Research on nisin spans over 80 years, with recent focus on therapeutic applications beyond food preservation. Current evidence includes 5 clinical trials and extensive preclinical studies.

Key Studies

Oral Cancer Clinical Trial (NCT06097468): Currently recruiting Phase I/II study evaluating nisin in oral cavity squamous cell carcinoma patients.

Peri-Implantitis Treatment (NCT07088679): Active trial testing natural bioactive gel containing nisin for dental implant infections.

NSCLC Research (2023): Pharmaceutical Research study demonstrated that nisin ZP induced cell death in non-small cell lung cancer cells in both 2D and 3D culture models, with IC50 values ranging from 100-500 μM.

SARS-CoV-2 Interaction (2021): Virology study showed nisin can bind to the SARS-CoV-2 spike protein receptor human ACE2, suggesting potential antiviral applications.

Oral Pathogen Inhibition (2014): Peptides journal study demonstrated significant antibacterial activity against oral pathogenic bacteria including Streptococcus mutans and Porphyromonas gingivalis.

Clinical Evidence

Five registered clinical trials are investigating nisin's therapeutic potential:

• Oral cancer treatment (Phase I/II)
• Peri-implantitis management
• Probiotic pathogen inhibition
• Gastrointestinal functional ingredients
• Antimicrobial gel efficacy

Dosage Guidelines

Therapeutic dosing protocols for nisin are still being established through clinical trials. Current research suggests highly variable dosing based on application:

Note: Therapeutic dosing protocols are not yet established for human use outside of clinical trials. Most research focuses on topical or localized administration rather than systemic dosing.

Safety Profile

Nisin has an extensive safety record as a food additive with GRAS (Generally Recognized as Safe) status. Therapeutic applications show promising safety profiles:

Common Effects: Minimal side effects reported in food additive use over decades.

Monitoring: Clinical trials monitor for:

• Local irritation at application sites
• Gastrointestinal tolerance
• Microbiome changes with prolonged use

Precautions:

• Individuals with dairy allergies should exercise caution
• Therapeutic doses may differ significantly from food preservative levels
• Limited data on long-term therapeutic use

Laboratory Monitoring: Not established for therapeutic applications; clinical trials include routine safety monitoring.

Stacking

Research suggests nisin may work synergistically with other antimicrobial compounds:

With Polymyxin B/Colistin: Network analysis studies indicate potential combination therapy benefits for resistant bacterial infections.

With Probiotics: Clinical trials investigate nisin's role in modulating beneficial bacteria while targeting pathogens.

With Conventional Antibiotics: Preclinical research suggests nisin may enhance the activity of traditional antibiotics against resistant strains.

Contraindicated Combinations: No specific contraindications established, but caution advised when combining with other antimicrobial agents that may affect microbiome balance.

Regulatory Note: Nisin is approved as a food preservative but remains investigational for therapeutic applications. Not approved for human medical use outside of clinical trials.

References

1. Antibacterial peptide nisin: a potential role in the inhibition of oral pathogenic bacteria. (2014). Peptides. DOI PubMed
2. Evaluation of antibacterial properties of nisin peptide expressed in carrots. (2023). Scientific reports. DOI PubMed
3. Recent Advances in the Application of the Antimicrobial Peptide Nisin in the Inactivation of Spore-Forming Bacteria in Foods. (2021). Molecules (Basel, Switzerland). DOI PubMed
4. A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2. (2021). Virology. DOI PubMed
5. Pulmonary delivery of spray-dried Nisin ZP antimicrobial peptide for non-small cell lung cancer (NSCLC) treatment. (2023). International journal of pharmaceutics. DOI PubMed
6. Mutagenesis of nisin's leader peptide proline strongly modulates export of precursor nisin. (2017). Antonie van Leeuwenhoek. DOI PubMed
7. A network perspective on antimicrobial peptide combination therapies: the potential of colistin, polymyxin B and nisin. (2017). International journal of antimicrobial agents. DOI PubMed
8. Nisin ZP, an Antimicrobial Peptide, Induces Cell Death and Inhibits Non-Small Cell Lung Cancer (NSCLC) Progression in vitro in 2D and 3D Cell Culture. (2022). Pharmaceutical research. DOI PubMed
9. Biomedical applications of nisin. (2016). Journal of applied microbiology. DOI PubMed
10. The nisin O cluster: species dissemination, candidate leader peptide proteases and the role of regulatory systems. (2025). Microbiology (Reading, England). DOI PubMed